Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race
Patients with mCRPC positive for HRR alterations tended to exhibit poorer treatment responses and clinical outcomes than those with a negative status. These findings highlight the importance of timely genetic testing in mCRPC, particularly among Black patients, and the need for improved 1L targeted therapies to address the unmet need in HRR positive mCRPC.
Authors
- Annalise Hilts
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Daniel J. George (ORCID: https://orcid.org/0000-0002-0836-8542)
- Mehmet Asım Bilen (ORCID: https://orcid.org/0000-0003-4003-1103)
- Ibrahim Khilfeh (ORCID: https://orcid.org/0000-0002-7677-2045)
- Erik Muser
- Laura Morrison (ORCID: https://orcid.org/0000-0001-5471-9932)
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
- Lilián Díaz (ORCID: https://orcid.org/0009-0006-6397-0129)
- Dominic Pilon
Institutions
- Emory University (US)
- Duke University (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/ceor.s468680
- Citations
- 2
- Primary Topic
- DNA Repair Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- American Society of Clinical Oncology
- Janssen Scientific Affairs